The Life Sciences team advised Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) on its definitive agreement with Catalent, Inc., for Catalent to acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash.
The transaction represents a total equity value of approximately $139.6 million on a fully-diluted basis, and a premium of 59.7% to Juniper’s unaffected share price on January 30, 2018, the last trading day prior to the date on which Juniper announced its intention to explore strategic alternatives.
Juniper's core businesses include its CRINONE® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients.
The Goodwin deal team was led by Michael Bison, Stuart Cable and James Matarese.
For additional details on the acquisition, please read the press release.